JP2019513395A5 - - Google Patents

Download PDF

Info

Publication number
JP2019513395A5
JP2019513395A5 JP2018554006A JP2018554006A JP2019513395A5 JP 2019513395 A5 JP2019513395 A5 JP 2019513395A5 JP 2018554006 A JP2018554006 A JP 2018554006A JP 2018554006 A JP2018554006 A JP 2018554006A JP 2019513395 A5 JP2019513395 A5 JP 2019513395A5
Authority
JP
Japan
Prior art keywords
seq
sequence
nucleic acid
effector
set forth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018554006A
Other languages
English (en)
Japanese (ja)
Other versions
JP7236195B2 (ja
JP2019513395A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2017/050330 external-priority patent/WO2017177277A1/en
Publication of JP2019513395A publication Critical patent/JP2019513395A/ja
Publication of JP2019513395A5 publication Critical patent/JP2019513395A5/ja
Application granted granted Critical
Publication of JP7236195B2 publication Critical patent/JP7236195B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018554006A 2016-04-14 2017-04-13 眼咽頭筋ジストロフィー(opmd)の処置のための試薬およびその使用 Active JP7236195B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662322745P 2016-04-14 2016-04-14
US62/322,745 2016-04-14
PCT/AU2017/050330 WO2017177277A1 (en) 2016-04-14 2017-04-13 Reagents for treatment of oculopharyngeal muscular dystrophy (opmd) and use thereof

Publications (3)

Publication Number Publication Date
JP2019513395A JP2019513395A (ja) 2019-05-30
JP2019513395A5 true JP2019513395A5 (enExample) 2020-04-23
JP7236195B2 JP7236195B2 (ja) 2023-03-09

Family

ID=60041243

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018554006A Active JP7236195B2 (ja) 2016-04-14 2017-04-13 眼咽頭筋ジストロフィー(opmd)の処置のための試薬およびその使用

Country Status (14)

Country Link
US (1) US11234994B2 (enExample)
EP (1) EP3443091A4 (enExample)
JP (1) JP7236195B2 (enExample)
KR (1) KR102353847B1 (enExample)
CN (1) CN109219659B (enExample)
AU (1) AU2017250017B2 (enExample)
CA (1) CA3020754C (enExample)
IL (1) IL262337B2 (enExample)
MX (1) MX2018012545A (enExample)
NZ (1) NZ747314A (enExample)
RU (1) RU2755544C2 (enExample)
SG (1) SG11201808981XA (enExample)
WO (1) WO2017177277A1 (enExample)
ZA (1) ZA201807589B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102353847B1 (ko) 2016-04-14 2022-01-21 베니텍 바이오파마 리미티드 안구인두 근이영양증(opmd)의 치료용 시약 및 이의 용도
US11142765B2 (en) 2016-12-14 2021-10-12 Benitec Ip Holdings, Inc. Reagents for treatment of oculopharyngeal muscular dystrophy (OPMD) and use thereof
CA3114945A1 (en) * 2018-10-17 2020-04-23 Benitec Biopharma Limited Methods for treating oculopharyngeal muscular dystrophy (opmd)

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677437A (en) 1990-07-27 1997-10-14 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
KR100211552B1 (ko) 1990-08-03 1999-08-02 디. 꼬쉬 유전자 발현 억제용 화합물 및 방법
US7015315B1 (en) 1991-12-24 2006-03-21 Isis Pharmaceuticals, Inc. Gapped oligonucleotides
US5719262A (en) 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US5633360A (en) 1992-04-14 1997-05-27 Gilead Sciences, Inc. Oligonucleotide analogs capable of passive cell membrane permeation
AU687736B2 (en) 1992-05-11 1998-03-05 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting viral replication
US5977343A (en) 1992-05-14 1999-11-02 Ribozyme Pharmaceuticals, Inc. Synthesis, deprotection, analysis and purification of RNA and ribozymes
WO1994022891A1 (en) 1993-03-31 1994-10-13 Sterling Winthrop Inc. Oligonucleotides with amide linkages replacing phosphodiester linkages
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5753613A (en) 1994-09-30 1998-05-19 Inex Pharmaceuticals Corporation Compositions for the introduction of polyanionic materials into cells
US6001311A (en) 1997-02-05 1999-12-14 Protogene Laboratories, Inc. Apparatus for diverse chemical synthesis using two-dimensional array
US6054576A (en) 1997-10-02 2000-04-25 Ribozyme Pharmaceuticals, Inc. Deprotection of RNA
EP2138191A1 (en) 1998-01-05 2009-12-30 University Of Washington Enhanced transport using membrane disruptive agents
US7273933B1 (en) 1998-02-26 2007-09-25 Isis Pharmaceuticals, Inc. Methods for synthesis of oligonucleotides
US6867294B1 (en) 1998-07-14 2005-03-15 Isis Pharmaceuticals, Inc. Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
US6995259B1 (en) 1998-10-23 2006-02-07 Sirna Therapeutics, Inc. Method for the chemical synthesis of oligonucleotides
US6465628B1 (en) 1999-02-04 2002-10-15 Isis Pharmaceuticals, Inc. Process for the synthesis of oligomeric compounds
WO2001053307A1 (en) 2000-01-21 2001-07-26 Geron Corporation 2'-arabino-fluorooligonucleotide n3'→p5'phosphoramidates: their synthesis and use
AU8695901A (en) 2000-09-01 2002-03-13 Ribozyme Pharm Inc Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives
RU2322500C2 (ru) 2000-12-01 2008-04-20 Макс-Планк-Гезелльшафт Цур Фердерунг Дер Виссеншафтен Е.Ф. Малые молекулы рнк, опосредующие интерференцию рнк
US20020130430A1 (en) 2000-12-29 2002-09-19 Castor Trevor Percival Methods for making polymer microspheres/nanospheres and encapsulating therapeutic proteins and other products
EP1390490B1 (en) 2001-05-24 2009-04-15 Genzyme Corporation Muscle-specific expression vectors
US7060498B1 (en) 2001-11-28 2006-06-13 Genta Salus Llc Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers
US20030215395A1 (en) 2002-05-14 2003-11-20 Lei Yu Controllably degradable polymeric biomolecule or drug carrier and method of synthesizing said carrier
US6989442B2 (en) 2002-07-12 2006-01-24 Sirna Therapeutics, Inc. Deprotection and purification of oligonucleotides and their derivatives
WO2004020605A2 (en) 2002-08-29 2004-03-11 The Board Of Trustees Of The Leland Stanford Junior University Circular nucleic acid vectors, and methods for making and using the same
DK2284266T3 (da) * 2002-11-14 2014-01-13 Thermo Fisher Scient Biosciences Inc sIRNA-MOLEKYLE MOD TP53
US7358223B2 (en) 2004-10-04 2008-04-15 Nitto Denko Corporation Biodegradable cationic polymers
AU2006204120A1 (en) 2005-01-06 2006-07-13 Benitec, Inc. RNAi agents for maintenance of stem cells
WO2007086883A2 (en) 2005-02-14 2007-08-02 Sirna Therapeutics, Inc. Cationic lipids and formulated molecular compositions containing them
US8110184B2 (en) * 2005-09-30 2012-02-07 University Of Kentucky Research Foundation Ex vivo and in vivo methods and related compositions for generating hematopoietic stem cell populations
EP2014281A1 (en) 2007-06-19 2009-01-14 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of inhibitors of sirtuins and/or ampk for the preparation of a medicament for the treatment of polyalanine diseases.
US20110224447A1 (en) 2008-08-18 2011-09-15 Bowman Keith A Novel Lipid Nanoparticles and Novel Components for Delivery of Nucleic Acids
WO2010042877A1 (en) 2008-10-09 2010-04-15 Tekmira Pharmaceuticals Corporation Improved amino lipids and methods for the delivery of nucleic acids
WO2010080724A1 (en) 2009-01-12 2010-07-15 Merck Sharp & Dohme Corp. Novel lipid nanoparticles and novel components for delivery of nucleic acids
CN102421900B (zh) 2009-03-12 2015-07-22 阿尔尼拉姆医药品有限公司 用于抑制Eg5和VEGF基因表达的脂质配制的组合物以及方法
US9181295B2 (en) 2009-08-20 2015-11-10 Sirna Therapeutics, Inc. Cationic lipids with various head groups for oligonucleotide delivery
JP2013519869A (ja) 2010-02-10 2013-05-30 ノバルティス アーゲー 筋肉成長のための方法および化合物
CN103403162A (zh) 2010-12-30 2013-11-20 陶氏益农公司 赋予对鞘翅目有害生物的抗性的核酸分子
KR101454425B1 (ko) 2012-10-11 2014-11-03 포항공과대학교 산학협력단 미리세틴을 유효성분으로 포함하는 운동수행능력 증강용 조성물
WO2014077693A1 (en) 2012-11-16 2014-05-22 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Means and methods for reducing an effect of aging in a mammalian cell
KR101683964B1 (ko) 2014-05-29 2016-12-09 연세대학교 산학협력단 Daxx의 발현을 억제하는 핵산 분자, TRAIL 유전자 및 Bcl-xL 의 발현을 억제하는 핵산 분자를 포함하는 재조합 발현 벡터
KR102353847B1 (ko) 2016-04-14 2022-01-21 베니텍 바이오파마 리미티드 안구인두 근이영양증(opmd)의 치료용 시약 및 이의 용도

Similar Documents

Publication Publication Date Title
EP2633051B1 (en) Hbv treatment
US9518260B2 (en) Pain treatment
CN101603042B (zh) 可用于乙型肝炎病毒感染治疗的rna干扰靶点
JP2005521393A5 (enExample)
JP2022185052A5 (enExample)
JP2025016451A5 (enExample)
JP2010500025A5 (enExample)
JP2019513395A5 (enExample)
AU2021213253A1 (en) Gene therapy for neurodegenerative disorders using polynucleotide silencing and replacement
JP2024119830A5 (enExample)
JP2020503014A5 (enExample)
CN103275971A (zh) 可用于乙型肝炎病毒感染治疗的rna干扰靶点
US9970004B2 (en) Nucleic acid molecule, expression cassette, expression vector, eukaryotic host cell, induction method of RNA interferencde in eukaryotic host and use of the nucleic acid molecule in therapy of diseases induced by expansion of trinucleotide CAG repeats
IL267353B2 (en) Reagents for the treatment of (OCULOPHARYNGEAL MUSCULAR DYSTROPHY (OPMD) and their uses
RU2018138271A (ru) Реагенты для лечения окулофарингеальной мышечной дистрофии (OPMD) и их применение
JP2019514401A5 (enExample)
EP2173900A2 (en) Hepatitis c dsrna effector molecules, expression constructs, compositions, and methods of use
RU2018142797A (ru) Средства для лечения инфекции вируса гепатита в (hbv) и их применение
JP2008503569A5 (enExample)
US9790502B2 (en) HBV treatment
JPWO2020061528A5 (enExample)
JPWO2020047476A5 (enExample)
JPWO2021020412A5 (enExample)
JPWO2020077412A5 (enExample)
Olson et al. Dual targeting of miR-208 and miR-499 in the treatment of cardiac disorders